Plk1 is upregulated in androgen-insensitive prostate cancer cells and its inhibition leads to necroptosis

Oncogene

Volumn 32, Issue 24, 2013, Pages 2973-2983

  Deeraksa, A ^a   Pan, J ^a   Sha, Y ^b   Liu, X D ^b   Eissa, N T ^b   Lin, S H ^c   Yu Lee, L Y ^a,d  

^a Section of Immunology Allergy and Rheumatology   (United States)

^b Department of Medicine   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

autophagy; BI2536; mitotic catastrophe; necroptosis; Plk1; prostate cancer

Indexed keywords

4 (8 CYCLOPENTYL 7 ETHYL 5,6,7,8 TETRAHYDRO 5 METHYL 6 OXO 2 PTERIDINYLAMINO) 3 METHOXY N (1 METHYL 4 PIPERIDINYL)BENZAMIDE; CASPASE 3; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; POLO LIKE KINASE 1;

ANDROGEN INSENSITIVITY SYNDROME; APOPTOSIS; ARTICLE; CANCER GROWTH; CASTRATION RESISTANT PROSTATE CANCER; CELL VIABILITY; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; LOW DRUG DOSE; M PHASE CELL CYCLE CHECKPOINT; MALE; MITOSIS; NECROPTOSIS; PRIORITY JOURNAL; TREATMENT RESPONSE; UPREGULATION;

ANDROGENS; ANEUPLOIDY; AUTOPHAGY; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MITOSIS; NECROSIS; PROSTATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; UP-REGULATION;

EID: 84879420631     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.309     Document Type: Article

References (41)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 43-66.
2. Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J et al. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 2009; 138: 245-256.
3. Barr FA, Sillje HH, Nigg EA. Polo-like kinases and the orchestration of cell division. Nat Rev Mol Cell Biol 2004; 5: 429-440.
4. Takaki T, Trenz K, Costanzo V, Petronczki M. Polo-like kinase 1 reaches beyond mitosis-cytokinesis, DNA damage response, and development. Curr Op Cell Biol 2008; 20: 650-660.
5. Wang LG, Ossowski L, Ferrari AC. Androgen receptor level controlled by a suppressor complex lost in an androgen-independent prostate cancer cell line. Oncogene 2004; 23: 5175-5184.
6. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM et al. LNCaP model of human prostatic carcinoma. Cancer Res 1983; 43: 1809-1818.
7. Lenart P, Petronczki M, Steegmaier M, Di Fiore B, Lipp JJ, Hoffmann M et al. The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of Pololike kinase 1. Curr Biol 2007; 17: 1-12.
8. Musacchio A, Salmon ED. The spindle assembly checkpoint in time and space. Nat Rev Mol Cell Biol 2007; 8: 379-393.
9. Macy B, Wang M, Yu H-G. The many faces of shugoshin, the 'guardian spirit', in chromosome segregation. Cell Cycle 2009; 8: 35-37.
10. Nishino M, Kurasawa Y, Evans R, Lin S-H, Brinkley BR, Yu-Lee L-y. NudC is required for Plk1 targeting to the kinetochore and chromosome congression. Curr Biol 2006; 16: 1414-1421.
11. Kurasawa Y, Yu-Lee L-y. PICH and cotargeted Plk1 coordinately maintain pro-metaphase chromosome arm architecture. Mol Biol Cell 2010; 21: 1188-1199.
12. Lee KS, Yuan YLO, Kuriyama R, Erikson RL. Plk is an M-phase-specific protein kinase and interacts with a kinesin-like protein, CHO1/MKLP-1. Mol Cell Biol 1995; 15: 7143-7151.
13. Jang Y-J, Ma S, Terada Y, Erikson RL. Phosphorylation of threonine 210 and the role of serine 137 in the regulation of mammalian polo-like kinase. Proc Natl Acad Sci 2002; 277: 44115-44120.
14. Culig Z, Hoffmann J, Erdel M, Eder IE, Hobisch A, Hittmair A et al. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumor progression in a new model system. Br J Cancer 1999; 81: 242-251.
15. Thalmann GN, Anezinis PE, Chang SM, Zhau HE, Kim EE, Hopwood VL et al. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res 1994; 54: 2577-2581.
16. Sramkoski RM, Pretlow II TG, Giaconia JM, Pretlow TP, Schwartz S, Sy M-S et al. A new human prostate carcinoma cell line 22Rv1. In Vitro Cell Dev Biol 1999; 35: 403-409.
17. Mizushima N, Komatsu M. Autophagy: renovation of cells and tissues. Cell 2011; 147: 728-741.
18. Caserta TM, Smith AN, Gultice AD, Reedy MA, Brown TL. Q-VD-OPh, a broad spectrum caspase inhibitor with potent antiapoptotic properties. Virology 2003; 191: 589-599.
19. Vakifahmetoglu H, Zhivotovsky B. Death through a tragedy: mitotic catastrophe. Cell Death Diff 2008; 15: 1153-1162.
20. Christofferson DE, Yuan J. Necroptosis as an alternative form of programmed cell death. Curr Op Cell Biol 2010; 22: 263-268.
21. Galluzzi L, Vitale I, Abrams JM, Alnemri ES, Baehrecke EH, Blagosklonny MV et al. Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Diff 2012 19: 107-120.
22. Castedo M, Perfettini J-L, Roumier T, Andreau K, Medema RH, Kroemer G. Cell death by mitotic catastrophe: a molecular definition. Oncogene 2004; 23: 2825-2837.
23. Degterev A, Huang Z, Boyce M, Li Y, Jagtap P, Mizushima N et al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol 2005; 1: 112-115.
24. Liu XS, Song B, Liu X. The substrates of Plk1, beyond the functions in mitosis. Protein Cell 2011; 1: 999-1010.
25. Strebhardt K. Multifacted polo-like kinases: drug targets and antitargets for cancer therapy. Nat Rev Drug Discovery 2010; 9: 643-660.
26. Smith MR, Wilson ML, Hamanaka R, Chase D, Kung H, Longo DL et al. Malignant transformation of mammalian cells initiated by constitutive expression of the polo-like kinase. Biochem Biophys Res Comm 1997; 234: 397-405.
27. Guan R, Tapang P, Leverson JD, Albert D, Giranda VL, Luo Y. Small-interfering RNA-mediated polo-like kinse 1 depletion preferentially reduces the survival of p53-defective, oncogenic transformed cells and inhibits tumor growth in animals. Cancer Res 2005; 65: 2698-2704.
28. Reagan-Shaw S, Ahmad N. Silencing of polo-like kinase (Plk) 1 via siRNA causes induction of apoptosis and impairment of mitosis machinery in human prostate cancer cells: implications for the treatment of prostate cancer. FASEB J 2005; 19: 611-613.
29. Schmit TL, Zhong W, Setaluri V, Spiegelman VS, Ahmad N. Targeted depletion of Polo-like kinase (Plk) 1 through lentiviral shRNA or a small molecule inhibitor causes mitotic catastrophe and induction of apoptosis in human melanoma cells. J Invest Dermatol 2009; 129: 2843-2853.
30. Park JE, Erikson RL, Lee KS. Feed-forward mechanism of converting biochemical cooperativity to mitotic processes at the kinetochore plate. Proc Natl Acad Sci 2011; 108: 8200-8205.
31. Li J, Wang J, Jiao H, Liao J, Xu X. Cytokinesis and cancer: Polo loves ROCK'n' Rho(A). J Genet Genomics 2010; 37: 159-172.
32. Zhou T, Aumais JP, Liu X, Yu-Lee L-y, Erikson RL. A role for Plk1 phosphorylation of NudC in cytokinesis. Dev Cell 2003; 5: 127-138.
33. Brennan IM, Peters U, Kapoor TM, Straight AF. Polo-like kinase controls vertebrate spindle elongation and cytokinesis. Proc Natl Acad Sci 2007; 91: 5046-5050.
34. Bastos RN, Barr FA. Plk1 negatively regulates Cep55 recruitment to the midbody to ensure orderly abscission. J Cell Biol 2010; 191: 751-760.
35. Artus C, Bouhrad H, Bouharrour A, Brunelle M-N, Hoos S, Yuste VJ et al. AIF promotes chromatinolysis and caspase-independent programmed necrosis by interacing with histone H2AX. EMBO J 2010; 29: 1585-1599.
36. Degterev A, Hitomi J, Germscheid M, Ch'en IL, Korkina O, Teng X et al. Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat Chem Biol 2008; 4: 313-321.
37. Hitomi J, Christofferson DE, Ng A, Yao J, Degterev A, Xavier RJ et al. Identification of a molecular signaling network that regulates a cellular necrotic cell death pathway. Cell 2008; 135: 1311-1323.
38. Vandenabeele P, Galluzzi L, Vanden Berghe T, Kroemer G. Molecular mechanisms of necroptosis: an ordered cellular explosion. Nat Rev Mol Cell Biol 2010; 11: 700-714.
39. Alano CC, Swanson RA. Players in the PARP-1 cell death pathway: JNK1 joins the cast. Trends Biochem Sci 2006; 31: 309-311.
40. Hanahan DJ, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
41. Speirs CK, Hwang M, Kim S, Li W, Chang S, Varki V et al. Harnessing the cell death pathway for targeted cancer treatment. Am J Cancer Res 2011; 1: 43-61.